综合系统方法在晚发性阿尔茨海默病中识别了遗传节点和网络
Bin Zhang1, Chris Gaiteri, Liviu-Gabriel Bodea
1Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. bin.zhang@mssm.edu
Cell
|April 30, 2013
概括
这项研究表明,晚期发病的阿尔茨海默病 (LOAD) 会改变大脑中的分子网络,特别是免疫和微质细胞模块. 这种网络结构有助于预测疾病机制和对基因变化的反应.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 系统生物学 系统生物学
背景情况:
- 像晚发性阿尔茨海默病 (LOAD) 这样的复杂疾病涉及细胞通路内的分子相互作用.
- 通过分子网络了解这些相互作用对于描述疾病机制至关重要.
研究的目的:
- 构建和分析大脑组织中的基因调节网络,以确定与LOAD相关的分子系统.
- 突出特定的网络结构和与LOAD病理相关的监管机构.
主要方法:
- 基因调节网络的构建,使用来自1647名LOAD患者和无痴呆症患者的死后脑组织.
- 一种基于网络的综合性方法,根据LOAD病理的相关性对网络结构进行排名.
- 对小鼠微质细胞的分析,以验证来自人类大脑网络的发现.
主要成果:
- 证明LOAD可以重新配置大脑中的分子相互作用结构的特定部分.
- 一个特定于免疫和微质细胞的模块被鉴定出来,由细胞酶基因主导,并由TYROBP调节,并且被发现在LOAD.中被上调.
- 鼠标微质细胞实验证实了与人类TYROBP网络的重叠表达变化.
结论:
- 基因调节网络结构对于理解LOAD病理和预测对遗传干扰的反应有价值.
- 已识别的免疫和微质模块为LOAD.中测试疾病模型提供了一个框架.
相关概念视频
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Protein Networks
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...


